




SARS-CoV-2-specific T-cell responses in COVID-19 patients

Rory D de Vries, PhD

Assistant Professor Department of Viroscience Erasmus MC, Rotterdam the Netherlands

Role for T-cells in COVID-19


COVID-19 patients present with low CD3⁺, CD4⁺ and CD8⁺ T cell counts



Lymphopenia is associated with disease severity

T-cell activation in COVID-19

Increase in activated T-cells in PBMC fraction during COVID-19






SARS-CoV-2-specific T-cells

- What do we know about SARS-CoV-2-specific T-cells?
 - ±10 published papers out, many more prepints
 - Lymphopenia and immune hyperresponsiveness complex interaction between SARS-CoV-2 and the immune system that is not fully understood
- Immune hyperreactivity and high levels of cytokines observed in severe COVID-19
 Zhou et al, La Evangelos et

 IL-6, IL-10, IP10, etc


Study cohort (Acute Respiratory Distress Syndrome)




Study cohort

CD3+ (%)

- N=10 COVID-19 ARDS patients (expanding)
- N=10 age-matched healthy controls




Erasmus MC University Medical Center Rotterdam SARS-CoV-2-specific CD4⁺ T-cells




MP_CD4_R MP_CD4_R Tcentral memory (T^{CM}) Teffector memory (T^{EM}) Tterminally differentiated (T^{EMRA}) Tnaive (T^N)



SARS-CoV-2-specific CD8⁺ T-cells



S, M and N are the prominent targets




SARS-CoV-2-specific T-cells - OVERVIEW


		CD4+ MP_S	CD4 ⁺ MP_CD4_R	CD8 ⁺ MP_S	CD8 ⁺ MP_CD8
Weiskopf et al, Sci Imm, 2020	HC	1/10 (10%)	2/10 (20%)	1/10 (10%)	0/10 (0%)
	COVID-19	40/45 (89%)	30/42 (71%)	27/45 (60%)	15/41 (37%)
Braun et al, Nature, 2020	HC	24/68 (35%)			
	COVID-19	15/18 (83%)			
Grifoni et al, Cell, 2020	HC	1/11 (9%)	4/11 (36%)		1/10 (10%)
	COVID-19	10/10 (100%)	10/10 (100%)		7/10 (70%)



Cross-reactive T-cells in HC



Cross-reactive T-cells in HC





Cross-reactive T-cells in HC

T-cell lines generated after peptide stimulation of PBMC from pre-pandemic donors


A	N ₃₂₆	В	S ₈₁₆ , donor 2209	С	S ₈ .	₁₆ , donor 2086	D		S ₁₂₀₆	
5000 4000- 3000- 4000- 4000- 4000- 4000- 4000- 4000- 4000- 4000- 4000- 4000- 4000- 4000- 4000- 4000- 40	Seasona	I HCoV	s likely i		e T-			cross-	react	
2000- 1000-	Cross-	reactive C	with S D4+ T-cells				ns /	eniton	A C	
1 0.1 Pep in Fluore	tide concentration pSPOT assay (μg/mL)		proSPOT assay (μg/mL)	target		de concentration SPOT assay (μg/mL)	/115 /	Pepti	es 0.001 0.0001 0.00 de concentration δPOT assay (μg/mL)	0001
 SARS-CoV- 229E HKU1 NL63 OC43 	PEGCVLTNTGSVVKP PGNTFITVEAAIELS PSVAVRTYSEAAAQG	100 ● SARS-Co 40 ■ 229E 40 ▲ HKU1 33 ● NL63 40 ◆ OC43	0V-2 SFIEDLLFNKVTLAD SAIEDILFSKLVTSG SFFEDLLFDKVKLSD SALEDLLFSKVVTSG SAIEDLLFDKVKLSD	47 73 53	 SARS-CoV-2 229E HKU1 NL63 OC43 	2 SFIEDLLFNKVTLAD SAIEDILFSKLVTSG SFFEDLLFDKVKLSD SALEDLLFSKVVTSG SAIEDLLFDKVKLSD	100 47 73 53 73	 SARS-CoV-2 229E HKU1 NL63 OC43 	YEQYIKWPWYIWLGF VETYIKWPWWVWLCI YEMYVKWPWYVWLLI FENYIKWPWWVWLII YEYYVKWPWYVWLLI	100 60 67 60 67



SARS-CoV-specific T-cells are long-lived

PBMC isolated from SARS recovered individuals 17 years after disease

Stimulated with N peptide pool



Summary and Discussion

- SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells detected in blood of COVID-19 patients
 - S, M and N are the dominant targets
- (Dominant effector and Th1) cytokine production in response to viral antigen

What is the role of (cross-reactive) T-cells

- Reactive T cells were detected in HC after MP stim in -> cross-reactivity
 Also reported by Grifoni et al (US), Braun et al (Germany), Le Bert et al (Sinapore) and Meckiff et al (UK)
 Possible induction by circu (prevention of), es disease??
- SARS-CoV-specific T-cells are long-lived
- Detection of SARS-CoV-2-specific T-cells is an accurate measure of exposure

Erasmus MC, Viroscience

- Katharina Schmitz
- Matthijs Raadsen
- Nisreen Okba
- Richard Molenkamp
- Marion Koopmans
- Bart Haagmans
- Eric van Gorp
- Rik de Swart

Erasmus MC, ICU

- Henrik Endeman
- Johannes vd Akker

LJI, San Diego, USA

- Daniela Weiskopf
- Alba Grifoni
- Alessandro Sette



Life Without Disease.

MegaPool (MP) stimulations

- Method: stimulate PBMC with peptide pools, detect T cell activation
- Specific peptide pools used (MegaPools, MPs)
 - MPs are pools with large numbers of peptides generated by sequential pooling and lyophilization.
 - Can incorporate overlapping peptides, or predicted or experimentally validated epitopes




Activation-Induced Markers (AIM)

- Method: stimulate PBMC with peptide pools, detect T cell activation
 - Upregulation of activation markers CD69 and CD137 (20h stimulation)
 - Intracellular detection of IFNγ and TNFα (8h stimulation)
 - Cytokines measured in culture sup with multiplex beads assay (20h stimulation)



Activation-Induced Markers (AIM)




Gating strategy:


- A: LIVE cells
- B: Lymphocytes FSC / SSC
- C: Single cells
- D: CD3⁺ cells
- E: CD4⁺ / CD8⁺ cells
- F/G: Memory phenotyping on basis of CD45RA / CCR7
- H: CD69 vs CD137 DMSO (- control)
- I: CD69 vs CD137 CMV (+ control)
- J: CD69 vs CD137 MP_S
- Double positive cells in J used in graphs



T-cells in absence of seroconversion








SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. We here systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in unexposed individuals, exposed family members, and individuals with acute or convalescent COVID-19. Acute phase SARS-CoV-2-specific T cells displayed a highly activated cytotoxic phenotype that correlated with various clinical markers of disease severity, whereas convalescent phase SARS-CoV-2-specific T cells were polyfunctional and displayed a stem-like memory phenotype. Importantly, SARS-CoV-2-specific T cells were detectable in antibody-seronegative exposed family members and convalescent individuals with a history of asymptomatic and mild COVID-19. Our collective dataset shows that SARS-CoV-2 elicits robust, broad and highly functional memory T cell responses, suggesting that natural exposure or infection may prevent recurrent

Sekine et al. Cell. 2020



Summary and Discussion



The Netherlands Organisation for Health Research and Development Programme: Off Road 2016-2017

Project summary

Coronaviruses are endemic in humans and often cause a self-limiting infection with common cold-like symptoms. Some of the zoonotic high-threat emerging viruses are also coronaviruses: MERS-coronavirus (CoV) has recently been identified as novel zoonotic agent and is continuing to spill over to humans. Virus-specific cytotoxic T-cells, considered crucial for viral clearance, have not yet been detected for human coronaviruses. The overall aim of this proposal is to detect T-cells specific for endemic- and MERS-CoV and determine whether these T-cells can be cross-reactive. This will be addressed by probing blood samples from unique MERS-CoV-infected patients from the Middle East for endemic coronavirus-specific, MERS-CoV-specific and cross-reactive T-cells. As a proof of principle, I will develop a mouse model to prove that endemic coronaviruses can protect from MERS-CoV-related disease.

Erasmus MC